Argonaut 2000 Partnerts Q1:22 Review and 2022 Look Ahead Strategy Webinar

SingularLogo

 

Argonaut 2000 Partners Q1:22 Review and 2022 Look Ahead Strategy Webinar

Thu, Apr 28, 2022 4:00 AM - 5:00 AM AWST

 

REGISTER NOW

 

Argonaut 2000 Partners LP is ranked in the top 1% of Long/Short equity funds since 1/1/19. Join us on Wednesday, April 27 at 1 pm PDT for a review of Q1:22 and forward fund managers' 2022 strategic outlook.

Topics and industries of discussion will include:

  • 2022 Outlook
  • Accessing value vs. growth
  • Macro market strategies & geopolitics
  • Responding to an aggressive Fed

 

We will be joined by: Chris Sakai, CFA covering timely opportunities for this market environment including (EBIX), Cannae Holdings Inc (CNNE), Crescent Point Energy Corp (CPG); Lisa Springer, MBA will discuss Salem Media Group Inc (SALM) and Entravision Communications Corp (EVC); Rob Shapiro, CFA will discuss Rocky Brands (RCKY) and Educational Development Corporation (EDUC).

Singular Research's Emerging Growth & Value Alpha Leaders Webinar

SingularLogo

 

 

Emerging Growth & Value Alpha Leaders Webinar

Thursday, February 24, 8:30 am - 4:00 pm PST

 

REGISTER NOW

 

Presentation Schedule (PST):

8:30 Socket Mobile, Inc., Kevin Mills, CEO
9:15 Voyager Digital, Ltd., Michael Legg, Chief Communications Officer
10:00 Mistras Group, Inc., Dennis Bertolotti, CEO
10:45 Esports Entertainment Group, Inc., Grant Johnson, CEO
11:30 ARC Document Solutions, Inc. David Stickney, VP of Corporate Communications
12:15 PM Canasil Resources, Inc., Bahman Yamini, CEO
1:00 Elenita, Jordan Dil, CEO
1:45 Acme United Corporation, Walter Johnsen, CEO
2:30 SenesTech, Inc., Kenneth Siegel, CEO

Argonaut Fund's 2021 Performance Review and 2022 Outlook

SingularLogo

Wednesday, January 26 at 2 pm PDT

 

 

DECEMBER TEARSHEET | REGISTER HERE

 

Argonaut 2000 Partners LP is ranked in the top 2% of Long/Short equity funds at Eureka Hedge since 1/1/19. Join us on Wednesday, January 26 at 2:00 pm PDT for a review of 2021 and fund managers' 2022 strategic outlook.

Topics and industries of discussion will include:

  • Value vs. growth in a higher yield environment
  • Why the Fed may not be able to stop inflation this time
  • Post pandemic repositioning
  • A new market beat? Downside & duration potential

We will be joined by: Chris Sakai, CFA and Rob Schapiro, CFA to discuss their top ideas for 2022.

Singular Research's Best of the Uncovered Webinar 12/9 at 6am PDT

SingularLogo

Thursday, December 8 at 6 am PDT

 

 

REGISTER NOW

 

Please save the date for our 16th annual "Best of the Uncovered" webinar on Thursday, December 9. This webinar is for our clients and select qualified institutional investors.

 

Presentation Schedule

(Time (PST), Ticker, Company Name, Presenter Name)
6:00 AM, HBIO, Harvard Bioscience, Inc., Mr. Michael A. Rossi, CFO
6:45 AM, EBS, Emergent BioSolutions, Inc., Mr. Robert Burrows, Chief Investor Relations Officer
7:30 AM, LUNA, Luna Innovations, Inc., Mr. Scott A. Graeff, Pres. & CEO
8:15 AM, SALM, Salem Media Group, Inc., Mr. Evan D. Masyr, Exec. VP & CFO
9:00 AM, BBKCF, BIGG Digital Assets, Inc., Mr. Mark Binns, CEO & Director
9:45 AM, MMAT, Meta Materials, Inc., Dr. George Palikaras, Ph.D., Founder, CEO, Pres, & Director
10:30 AM, FSTR L.B., Foster Company, Mr. John F. Kasel, Pres, CEO, & Director
11:15 AM, --, Singular Research Special Situations, Mr. Christopher J. Sakai, CFA
12:00 PM, ACU, Acme United Corporation, Mr. Walter C. Johnsen, Chairman & CEO
12:45 PM, SCKT, Socket Mobile, Inc., Mr. Kevin J. Mills, Pres., CEO, & Director
1:30 PM, DRSSF, Arianne Phosphate, Inc., Mr. Brian Richard Ostroff, Pres. & Director
2:15 PM, CXDO Crexendo, Inc., Mr. Douglas Walter Gaylor, COO & Pres.
3:00 PM, BMTX BM Technologies, Inc., Mr. Robert Hutcheson Ramsey, CFA, CFO

LUNA Innovations: Managements Focus On Shareholder Value Is Superb

SingularLogo

 

LUNA Innovations: Managements Focus On Shareholder Value Is Superb

LUNA Innovations Inc. develops and markets fiber optic sensing, and test and measurement products worldwide. The company has two operating segments. The products and licensing unit sells the company’s commercial fiber optic test and sensing equipment and the technology development segment performs contract R&D for U.S. government agencies.

 

November 19, 2021

Price (as of close on Nov 18, 2021)

$9.38

Rating

BUY

Price Target

blocked

 

 

LUNA Innovations Inc. (LUNA)

The Company reported weak third quarter 2021 results impacted by ongoing supply chain challenges globally. The planned divestment of the slow growing, low margin LUNA Labs business is a positive. blockedblockedblockedblockedblockedblocked     

luna nov 2021

 

Q3:21 Highlights

➢ LUNA announced plans to divest their LUNA Labs business. As of the beginning of Q3, the business has been moved to discontinued operations.

➢ Q3:21 revenues were $20.3 million, up 32% versus Q3:20, largely attributable to the acquisition of OptaSense in December 2020.

LUNA reported a 31% YOY increase in gross profit to $12.5 million. Gross margin decreased by ~100 bps YOY to 62%.

➢ Adjusted EBITDA decreased to $2.1 million, compared to $3.1 million for Q3:20.

➢ LUNA noted that the Company continues to be challenged by supply chain issues which is impacting revenue growth despite strong demand.

➢ For the full year, LUNA revised its 2021 revenue outlook to factor in LUNA Labs as a discontinued operation and supply chain headwinds. Revenue and adjusted EBITDA are now expected to be between $85-$88 million and $6-$8 million, respectivel

blockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblockedblocked     

 

PRIMARY RISKS

➢ The Company operates in a space which is prone to rapid technological changes. New technology or the emergence of new industry standards could render existing products obsolete.

➢ Difficulties with integrating acquisitions could adversely affect operating costs and expected benefits from those acquisitions.

 

We at Singular Research hope you enjoyed this article and would like to invite you to try the full version of our service for free for 2-weeks on Seeking Alpha. 

Please click here for your free trial!

Emergent BioSolutions: A Great Value Proposition Emergent BioSolutions (EBS)

SingularLogo

 

Emergent BioSolutions: A Great Value Proposition Emergent BioSolutions (EBS)

Emergent BioSolutions (EBS) is a global specialty life sciences company that develops and commercializes vaccines, drugs and devices that address public health biodefense threats. The Company is a preferred provider of biodefense products and services to the U.S. government under multi-year contracts. Its portfolio includes the only FDA-approved anthrax vaccine and smallpox vaccine and NARCAN nasal spray for treating opioid overdose. The Company’s products are sold mainly in the U.S. as well as internationally.

 

November 8, 2021

Price (as of close on November 5, 2021)

$33.11

Rating

BUY

New 12- Month Target Price

blocked

 

Emergent BioSolutions

EBS shares tumble after termination of CIADM contract. JNJ COVID vaccine and other vaccines and products remain on track. We maintain our Buy rating, . blockedblockedblockedblockedblockedblockedblocked

 

ebs nov 2021

 

Q3:21 Highlights

➢ Termination of US government contract for pandemic preparedness reduces revenues to be realized under related task orders by $180 million while accelerating recognition of $60 million of deferred revenues.

➢ This contract termination has no impact on manufacturing of the JNJ COVID vaccine, which is a commercial order. EBS resumed manufacturing of the COVID vaccine in July and has to-date produced over 100 million doses.

➢ EBS secures a COVID vaccine manufacturing contract with Providence Therapeutics valued at $90 million over five years.

➢ The company’s CDMO business secured $118 million new business during the September quarter and ended the quarter with backlog of $1.0 billion.

➢ Sales of ACAM2000 smallpox vaccine rose $79.7 million as the company commenced deliveries under a contract option valued at $182 million. Sales of NARCAN nasal spray rose 50% to $133.3 million and EBS increased full-year guidance for this product to $400-$420 million from $305-$325.million earlier.

➢ Phase III trials began of the company’s chikungunya vaccine candidate and of its COVID-HIG therapeutic candidate for outpatient treatment of those at risk of severe forms of COVID.

➢ We updated our revenue and adjusted EPS estimates to reflect September quarter results and reduced guidance. We maintain our BUY rating blockedblockedblockedblockedblockedblocked

 

We at Singular Research hope you enjoyed this article and would like to invite you to try the full version of our service for free for 2-weeks on Seeking Alpha. 

Please click here for your free trial!

 

Acme United Corp: Management's Supply Chain Preparation Helping Lead Record Sales And Earnings In 2021

SingularLogo

 

Acme United Corp: Management's Supply Chain Preparation Helping Lead Record Sales And Earnings In 2021

Acme United Corporation is one of the largest worldwide suppliers of innovative cutting devices, measuring instruments and safety products for the school, home, office and industrial markets. The company has facilities in the U.S., Canada, England, Germany, Hong Kong and China.

 

November 11, 2021

Price (as of close on Nov 10, 2021)

$36.60

Rating

BUY

Price Target

blocked

 

Acme United Corp. (ACU)

ACU reported strong Q3:21 results with revenue up 11% YOY and net income up ~30% YOY. The management noted that it anticipates record sales and earnings in 2021. The supply chain challenges will continue in 2022, however ACU noted that it is well prepared given inventory stock-up over the last 18 months. We increase our target price blockedblockedblockedblocked    and maintain BUY on the stock.

 

acme nov 2021

 

Q3:21 Highlights

Q3:21 revenues were $47.9 million, up ~11% from Q3:20. The performance was strong across US (+12% YOY) and Canada (+6% YOY), while Europe was flat YOY.

Gross Margin for Q3:21 was 35.5%, which was up 100 bps compared to 34.5% in Q3:20.

Operating profit up 39.4% YOY on account of higher revenue and improved gross margins.

Net income for Q3:21 was $2.0 million vs. ~$1.5 million in Q3:20. The diluted EPS was $0.50 in Q3:21, vs. $0.46 in Q3:20, an increase of ~8.6%.

The company anticipates record sales and earnings in 2021.

We marginally adjust our earnings estimate factoring in the latest management commentary. We increase our target price to blockedblockedblockedblockedblockedblockedblockedblocked

 

PRIMARY RISKS

ACU’s results can be negatively impacted by weak economic activity; rising commodity input costs; timing of customer orders; foreign exchange fluctuations; and competitor pricing.

Failure to integrate acquisitions could adversely impact business operations.

 

We at Singular Research hope you enjoyed this article and would like to invite you to try the full version of our service for free for 2-weeks on Seeking Alpha. 

Please click here for your free trial!

Singular Research's Private Client call with Olympic Steel (ZEUS) Wednesday 12/1 at 9am PDT

SingularLogo

 

Private Client call with Olympic Steel (ZEUS) Wednesday 12/1 at 9am PDT

 

REGISTER NOW

 

Join us for a private client webinar with CEO Richard Marabito and CFO Rich Manson of Olympic Steel (ZEUS) on Wednesday, December 1 at 9 am PDT.Olympic Steel is a leading U.S. metals service center focused on the direct sale and distribution of large volumes of processed carbon, coated and stainless flat-rolled sheet, coil and plate steel, aluminum, tin, pipe, and tubular products.Olympic Steel, Inc., a leading national metals service center, announced record quarterly financial results for the three months ended September 30, 2021. Net income for the third quarter totaled $44.5 million, or $3.87 per diluted share, compared with a net loss of $1.5 million, or $0.13 per diluted share, in the third quarter of 2020. The Company reported sales totaling $668 million for the third quarter of 2021, compared with $300 million in the third quarter of 2020.

After registering, you will receive a confirmation email containing information about joining the webinar.